ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program
TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced investment commitment of €13.5M from the European Innovation Council’s (EIC) Accelerator program, including a grant of €2.5M and a conditional equity investment … Continued
ImPact Biotech Presents Additional Interim Data from ENLIGHTED Study of Padelipor n VTP in Low Grade Upper Tract Urothelial Cancer
Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of patients who completed the Induction Treatment Phase Padeliporfin VTP safe and efficacious, consistent with prior results and reinforcing initial clinical data from ENLIGHTED Preliminary efficacy data presented in a poster session at ASCO; additional interim … Continued
ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated, consistent with prior results and reinforcing differentiated organ-sparing profile Preliminary data presented in a podium session at AUA; additional interim results to be presented at ASCO TEL AVIV, Israel, May 06, 2024 (GLOBE NEWSWIRE) — … Continued
ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporn VTP in Low Grade UTUC at Upcoming Medical Conferences
Preliminary results from Phase 3 ENLIGHTED study in low grade upper tract urothelial cancer (UTUC) to be presented at AUA and ASCO Trial design for Phase 1 study of Padeliporfin VTP in pancreatic ductal adenocarcinoma (PDAC) to be presented at ASCO TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology … Continued
ImPact Biotech Announces Appointment of Eyal Morag, M.D. as Chief Medical Officer
TEL AVIV, Israel, Dec. 18, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat a range of solid tumors, today announced the appointment of Eyal Morag, M.D., as Chief Medical Officer (CMO). Dr. Morag brings extensive experience as a practicing clinical radiologist, specializing in … Continued